Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC | MicrobiomeTrials← Back to trialsNCT04937660
Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC
CompletedOBSERVATIONAL
Trial Details
Start: 2021-07-15Est. Completion: 2025-04-29
Enrollment target: 185 participants Locations- Alexandria School of Medicine/Clinical Research Center CRC, Alexandria, Egypt
- Dar El Salam Oncology Hospital, Cairo, Egypt
- National Cancer Institute, Cairo, Egypt
- Ain Shams University Hospital, Cairo, Egypt
- King Hussein Cancer Center, Amman, Jordan
- American University of Beirut Medical Center, Beirut, Lebanon
- Hôtel Dieu de France (HDF), Beirut, Lebanon
- Saint Joseph Hospital - Cancer Centers of Colorado, Jdeidé - Metn, Lebanon
- Hammoud Hospital University Medical Center (HHUMC), Sidon, Lebanon
- Hamad Medical Corporation, Doha, Qatar
- King Fahad Specialist Hospital KFSH-Dammam, Dammam, Saudi Arabia
- National Guard Hospital, Riyadh, Riyadh, Saudi Arabia
Other microbiome trials you might be interested in
Breast CancerSolid Tumor
This is an open-label, multicenter, Phase I study designed to evaluate the safety, tolerability, and pharmacokinetics of…
Boston, United StatesEst. completion Dec 31, 2026
HER2-positive Breast Cancer
The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecita…
Clayton, AustraliaEst. completion May 1, 2029